Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamidoxime SCHEMBL102483 | 1.00 | KMT2A (0.58) | KMT2AMEN1GAAPOLBCYP2C19 | |
| Benzamidoxime SCHEMBL30242 | 1.00 | KMT2A (0.58) | KMT2AMEN1GAAPOLBCYP2C19 | |
| SCHEMBL22872296 | 1.00 | KMT2A (0.58) | KMT2AMEN1GAAPOLBCYP2C19 | |
| Benzamidoxime SCHEMBL9211538 | 0.97 | KMT2A (0.56) | KMT2AMEN1GAAPOLBCYP2C19 | |
| Benzamidoxime SCHEMBL27457742 | 0.97 | POLB (0.58) | KMT2AMEN1GAAPOLBCYP2C19 | |
| Benzamidoxime SCHEMBL23405829 | 0.91 | CYP2C19 (0.52) | KMT2AMEN1GAAPOLBCYP2C19 | |
| Benzamidoxime SCHEMBL28695169 | 0.91 | CYP2C19 (0.57) | KMT2AMEN1GAAPOLBCYP2C19 | |
| Benzamidoxime SCHEMBL10502994 | 0.91 | MEN1 (0.50) | KMT2AMEN1GAAPOLBCYP2C19 | |
| SCHEMBL21215226 | 0.89 | GFER (0.55) | KMT2AMEN1GAAPOLBCYP2C19 | |
| Benzamidoxime SCHEMBL27799692 | 0.89 | F2 (0.70) | KMT2AMEN1GAAPOLBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| EP-3124472-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-07-25 | — | — | EP | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| EP-3124472-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2017-02-01 | — | — | EP | disclosed |
| US-20160206621-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2016-07-21 | — | — | US | disclosed |
| US-20160206621-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2016-07-21 | — | — | US | disclosed |
| US-9388172-B2 | Substituted carbamate compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2797888-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2016-06-08 | — | — | EP | disclosed |
| EP-2619190-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | Bristol-Myers Squibb Company (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013097224-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013000994-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-01-03 | — | — | WO | disclosed |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT LABORATORIES (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2012040532-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206621-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KMT2A 1652/4885MEN1 1687/4885GAA 2980/4885 |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | KMT2A 2687/4885MEN1 483/4885GAA 832/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | KMT2A 3518/4885MEN1 869/4885GAA 622/4885 |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | KMT2A 4230/4885MEN1 677/4885GAA 4510/4885 |
| US-20130005705-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | KMT2A 737/4885MEN1 4110/4885GAA 165/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | KMT2A 2682/4885MEN1 454/4885GAA 801/4885 |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | KMT2A 737/4885MEN1 4110/4885GAA 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.